Monitoring cancer patients in remission is a practice taking big steps forward thanks in part to Adaptive Biotechnologies' clonoSEQ service and its ability to look at immune systems for signs they're battling diseases on a level that older screening methods can't see.If Amgen is running clinical trials with a COVID-19 treatment candidate discovered in partnership with Adaptive, the big biotech is keeping it secret along with any financial details of their months-old collaboration.